MRT67307

MRT67307 is a potent, cell-permeable, small-molecule kinase inhibitor that targets TANK-binding kinase 1 (TBK1), IκB kinase epsilon (IKKε), UNC-51-like kinase 1 (ULK1), and UNC-51-like kinase 2 (ULK2). Developed by the University of Dundee, MRT67307 inhibits TBK1 and IKKε with IC50 values of 19 nM and 160 nM, respectively, and inhibits ULK1 and ULK2 with IC50 values of 45 nM and 38 nM, respectively. It also inhibits salt-inducible kinases (SIK1, SIK2, and SIK3) and microtubule affinity-regulating kinases (MARK1-4). By inhibiting TBK1 and IKKε, MRT67307 prevents the phosphorylation of interferon regulatory factor 3 (IRF3) and the subsequent production of interferon-beta (IFN-β). Through its inhibition of ULK1 and ULK2, it blocks autophagy in cells, leading to the accumulation of stalled early autophagosomal structures. It is widely utilized as a research tool to study innate immune signaling, autophagy, and mitotic progression in cancer cells.

Other names

MRT67307 HClMRT-67307 HClMRT 67307 HClMRT67307 hydrochlorideMRT-67307 hydrochlorideMRT 67307 hydrochlorideN-[3-[[5-cyclopropyl-2-[[3-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]propyl]-cyclobutanecarboxamide